Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Brain Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
CNS Tumor (517
)
Medulloblastoma (29
)
CNS Tumor (517
)
Medulloblastoma (29
)
›
Associations
(510)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MGMT unmethylation
Glioma
MGMT unmethylation
Glioma
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 1 week (New B)
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 1wk
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 1 week
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 1 week - (New B)
EGFR amplification
Glioblastoma
EGFR amplification
Glioblastoma
nivolumab + bevacizumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
nivolumab + bevacizumab
Resistant
:
C3
Cancer Immunol Immunother - 1wk
nivolumab + bevacizumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week
nivolumab + bevacizumab
Resistant
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression
Glioblastoma
PD-L1 overexpression
Glioblastoma
nivolumab + bevacizumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
nivolumab + bevacizumab
Sensitive
:
C3
Cancer Immunol Immunother - 1wk
nivolumab + bevacizumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week
nivolumab + bevacizumab
Sensitive
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
EGFR amplification
Glioblastoma
EGFR amplification
Glioblastoma
pembrolizumab + bevacizumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
pembrolizumab + bevacizumab
Resistant
:
C3
Cancer Immunol Immunother - 1wk
pembrolizumab + bevacizumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week
pembrolizumab + bevacizumab
Resistant
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression
Glioblastoma
PD-L1 overexpression
Glioblastoma
pembrolizumab + bevacizumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
pembrolizumab + bevacizumab
Sensitive
:
C3
Cancer Immunol Immunother - 1wk
pembrolizumab + bevacizumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week
pembrolizumab + bevacizumab
Sensitive
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
EGFR amplification
Glioblastoma
EGFR amplification
Glioblastoma
nivolumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
nivolumab
Resistant
:
C3
Cancer Immunol Immunother - 1wk
nivolumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week
nivolumab
Resistant
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression
Glioblastoma
PD-L1 overexpression
Glioblastoma
nivolumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
nivolumab
Sensitive
:
C3
Cancer Immunol Immunother - 1wk
nivolumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week
nivolumab
Sensitive
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
PD-L1 overexpression
Glioblastoma
PD-L1 overexpression
Glioblastoma
pembrolizumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
pembrolizumab
Sensitive
:
C3
Cancer Immunol Immunother - 1wk
pembrolizumab
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 1 week
pembrolizumab
Sensitive
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
EGFR amplification
Glioblastoma
EGFR amplification
Glioblastoma
pembrolizumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week (New C3)
pembrolizumab
Resistant
:
C3
Cancer Immunol Immunother - 1wk
pembrolizumab
Resistant: C3 – Early Trials
Cancer Immunol Immunother - 1 week
pembrolizumab
Resistant
:
C3
Cancer Immunol Immunother - 1 week - (New C3)
No biomarker
Glioblastoma
No biomarker
Glioblastoma
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Brain Cancer
No biomarker
Brain Cancer
lomustine
Sensitive: A1 - Approval
lomustine
Sensitive
:
A1
lomustine
Sensitive: A1 - Approval
lomustine
Sensitive
:
A1
No biomarker
Astrocytoma
No biomarker
Astrocytoma
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
No biomarker
Astrocytoma
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Ependymoma
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Anaplastic Astrocytoma
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Glioma
No biomarker
Glioma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Glioma
No biomarker
Glioma
teserpaturev
Sensitive: A1 - Approval
teserpaturev
Sensitive
:
A1
teserpaturev
Sensitive: A1 - Approval
teserpaturev
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
IDH1 mutation
Astrocytoma
IDH1 mutation
Astrocytoma
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
BRAF V600E
Glioblastoma
BRAF V600E
Glioblastoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
No biomarker
Anaplastic Astrocytoma
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
No biomarker
Glioma
No biomarker
Glioma
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
MGMT promoter methylation
Glioblastoma
MGMT promoter methylation
Glioblastoma
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
No biomarker
Glioma
No biomarker
Glioma
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
No biomarker
Meningioma
No biomarker
Meningioma
bevacizumab + everolimus
Sensitive: A2 - Guideline
bevacizumab + everolimus
Sensitive
:
A2
bevacizumab + everolimus
Sensitive: A2 - Guideline
bevacizumab + everolimus
Sensitive
:
A2
No biomarker
Meningioma
No biomarker
Meningioma
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
No biomarker
Meningioma
No biomarker
Meningioma
sunitinib
Sensitive: A2 - Guideline
sunitinib
Sensitive
:
A2
sunitinib
Sensitive: A2 - Guideline
sunitinib
Sensitive
:
A2
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
cisplatin + cyclophosphamide + vincristine
Sensitive
:
A2
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
cisplatin + cyclophosphamide + vincristine
Sensitive
:
A2
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
cisplatin + vincristine + lomustine
Sensitive: A2 - Guideline
cisplatin + vincristine + lomustine
Sensitive
:
A2
cisplatin + vincristine + lomustine
Sensitive: A2 - Guideline
cisplatin + vincristine + lomustine
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Glioma
No biomarker
Glioma
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login